Treatment group | Disease stages | Mean (Pg/ml) | Std. Dev | N | Mean diff ± S.E | p-value |
Pretreatment | ESBC | 102.24 | 34.09 | 28 | 9.96 ± 7.29 | 0.175 |
| ASBC | 92.29 | 24.03 | 40 |
|
|
| ESBC | 102.24 | 34.09 | 28 | 16.76 ± 9.27 | 0.074 |
| AHMC | 85.49 | 22.32 | 21 |
|
|
| ESBC | 102.24 | 34.09 | 28 | 5.06 ± 8.32 | 0.545 |
| BBT | 97.19 | 36.12 | 21 |
|
|
| ASBC | 92.29 | 24.03 | 40 | 6.80 ± 8.75 | 0.439 |
| AHMC | 85.49 | 22.32 | 21 |
|
|
| ASBC | 92.29 | 24.03 | 40 | 4.90 ± 7.74 | 0.528 |
| BBT | 97.19 | 36.12 | 21 |
|
|
| BBT | 97.19 | 36.12 | 21 | 11.70 ± 9.63 | 0.227 |
| AHMC | 85.49 | 22.32 | 21 |
|
|
3 months post-treatment | ESBC | 95.64 | 38.89 | 28 | 96.24 ± 56.14 | 0.090 |
| ASBC | 191.88 | 366.68 | 38 |
|
|
| ESBC | 95.64 | 38.89 | 28 | 10.15 ± 71.40 | 0.887 |
| AHMC | 85.49 | 22.32 | 21 |
|
|
| ESBC | 95.64 | 38.89 | 28 | 17.19 ± 64.91 | 0.792 |
| BBT | 78.45 | 11.13 | 20 |
|
|
| ASBC | 191.88 | 366.68 | 38 | 106.39 ± 67.39 | 0.118 |
| AHMC | 85.49 | 22.32 | 21 |
|
|
| ASBC | 191.88 | 366.68 | 38 | 113.43 ± 60.47 | 0.064 |
| BBT | 78.45 | 11.13 | 20 |
|
|
| BBT | 78.45 | 11.13 | 20 | 7.04 ± 74.86 | 0.925 |
| AHMC | 85.49 | 22.32 | 21 |
|
|
6 months post-treatment | ESBC | 93.78 | 22.12 | 26 | 17.03 ± 10.14 | 0.097 |
| ASBC | 102.70 | 46.72 | 31 |
|
|
| ESBC | 93.78 | 22.12 | 26 | 8.30 ± 12.52 | 0.051 |
| AHMC | 85.49 | 22.32 | 21 |
|
|
| ESBC | 93.78 | 22.12 | 26 |
|
|
| BBT | - | - | - |
|
|
| ASBC | 102.70 | 46.72 | 31 | 25.33 ± 11.83 | 0.036 |
| AHMC | 85.49 | 22.32 | 21 |
|
|
| ASBC | 102.70 | 46.72 | 31 |
|
|
| BBT | - | - | - |
|
|
| BBT | - | - | - |
|
|
| AHMC | 85.49 | 22.32 | 21 |
|
|